ST’s Tankyrase Inhibitor Moves Ahead With Govt Support
This article was originally published in PharmAsia News
South Korea’s ST Pharm is set to benefit from a government R&D support program for the development of a tankyrase inhibitor to treat KRAS mutant colorectal cancer. Through rapid preclinical testing, the affiliate of Dong-A Socio Holdings hopes to receive IND approval from the US FDA by the end of next year to begin clinical trials in the US.
You may also be interested in...
Among the Korean firms presenting at J.P. Morgan, Hanmi laid out its strategy for obesity and other core pipeline assets, Celltrion focused on its expanding biosimilar pipeline and China plans and LG Chem unveiled new R&D progress.
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.
After a year full of disappointing and unexpected events, the South Korean pharma sector is hoping for a turnaround in 2020, with expected biosimilar launches in global markets, progress in drug pipelines, large IPOs and implementation of a new law on cutting-edge biologics.